Takeda Enters 3-Year IBD Research Partnership with University of Chicago and Mount Sinai

Takeda Enters 3-Year IBD Research Partnership with University of Chicago and Mount Sinai
Takeda Pharmaceuticals U.S.A. announced that it has entered into a three-year partnership with two academic centers to further inflammatory bowel disease (IBD) research and patient care. The centers, The University of Chicago and the Icahn School of Medicine at Mount Sinai in New York, will advance research into IBD, and Takeda will translate scientific findings into new treatments and patient-focused support. The initiatives will focus on IBD and immunology (Mount Sinai), and IBD and digital innovation (University of Chicago). "Creating strong partnerships with the potential to discover game changing technologies and
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *